CMPX shares slump after FDA recommends additional cancer trial
Compass Therapeutics shares fell more than 25% after the FDA recommended an additional trial for its lead cancer drug, potentially delaying commercialization.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.